Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents

Expert Review of Anticancer Therapy

Volumn 14, Issue 5, 2014, Pages 523-542

  Vano, Yann Alexandre ^a   Tartour, Eric ^b   Fournier, Laure S ^a   Beuselinck, Benoit ^c   Mejean, Arnaud ^a   Oudard, Stephane ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

mTOR; Predictive factor; prognostic factor; renal cell carcinoma; TKI; VEGF targeted therapy

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; C REACTIVE PROTEIN; CARBONATE DEHYDRATASE IX; EVEROLIMUS; INTERLEUKIN 6; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN; ANTINEOPLASTIC AGENT; PLACEBO; VASCULOTROPIN A;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE MARKER; DRUG CHOICE; DRUG RESPONSE; DRUG TARGETING; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; HYPOXIA; INFLAMMATION; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MOLECULARLY TARGETED THERAPY; NEUTROPHIL COUNT; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SARCOMATOID CARCINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL PREDICTION; SURVIVAL TIME; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL (TOPIC); KIDNEY NEOPLASMS; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; PLACEBOS; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899026220     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.882773     Document Type: Review

References (150)

1. Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. Eur Urol 2011;60(4):615-21
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2):69-90
3. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007;13(2 Pt 2):671s-9s
4. Lopez-Beltran A, Carrasco JC, Cheng L, et al. 2009 update on the classification of renal epithelial tumors in adults. Int J Urol 2009;16(5):432-43
5. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353(23): 2477-90
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2):115-124
7. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-96
8. Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7): vii65-71
9. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; 25(1):CD001425
10. Wahlgren T, Harmenberg U, Sandstrom P, et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). Br J Cancer 2013; 108(7):1541-9
11. Schutz FA, Je Y, Richards CJ, Choueiri TK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012;30(8):871-7
12. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8): 2530-40
13. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96
14. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454-63
15. Procopio G, Verzoni E, Iacovelli R, et al. Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. Br J Cancer 2012; 107(8):1227-32
16. Motzer RJ, Escudier B, Bukowski R, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 2013;108(12):2470-7 . Pooled data (1059 patients from 6 trials) were used to identify 10 independent prognostic factors for survival in metastatic renal cell carcinoma (mRCC) patients (ethnic origin, Eastern Cooperative Oncology Group performance status, time from diagnosis to treatment, prior cytokine use, hemoglobin, lactate dehydrogenase, corrected calcium, neutrophils, platelets and bone metastases).
17. Molina AM, Jia X, Feldman DR, et al. Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer 2013;11(3): 297-302
18. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27(34):5794-9 . Four of the five prognostic factors of the memorial sloan kettering cancer center model were independent predictors of short survival (hemoglobin # normal, corrected calcium normal, Karnofsky PS
19. Bamias A, Tzannis K, Beuselinck B, et al. Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration. Br J Cancer 2013;109(2):332-41
20. Patil S, Figlin RA, Hutson TE, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011;22(2): 295-300
21. Beuselinck B, Oudard S, Rixe O, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011; 22(4):794-800
22. Ito K, Asano T, Yoshii H, et al. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 2006; 13(11):1365-70
23. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 2007;99(1):77-80
24. Johnson TV, Abbasi A, Owen-Smith A, et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J Urol 2010;183(2):480-5
25. Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007;110(6):1241-7
26. Fujita T, Iwamura M, Ishii D, et al. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol 2012;19(10): 908-13
27. Kusuda Y, Miyake H, Behnsawy HM, et al. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. Urol Oncol 2013; 31(1):42-50
28. Yasuda Y, Saito K, Yuasa T, et al. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 2013;18(5):884-9
29. Beuselinck B, Vano YA, Oudard S, et al. Pronostic impact of baseline serum c-reactive protein in metastatic renal cell carcinoma treated with sunitinib. BJU Int 2013. [Epub ahead of print]
30. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15(2):74-80
31. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265(3):621-36
32. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002; 4(3):250-5
33. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acutephase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997; 33(11):1794-8
34. Pelliniemi TT, Irjala K, Mattila K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995;85(3):765-71
35. Tartour E, Blay JY, Dorval T, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996;14(5):1697-703
36. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012;13(8):827-37
37. Bambury RM, Teo MY, Power DG, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 2013;114(1):149-54
38. Ishizuka M, Nagata H, Takagi K, et al. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer 2013;109(2):401-7
39. Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013;109(2):416-21
40. Pichler M, Hutterer GC, Stojakovic T, et al. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 2013; 109(5):1123-9
41. Keizman D, Ish-Shalom M, Huang P, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 2012;48(2):202-8
42. Cetin B, Berk V, Kaplan MA, et al. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma Clin Genitourin Cancer 2013; 11(2):141-8
43. Siemeister G, Weindel K, Mohrs K, et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996; 56(10):2299-301
44. Paradis V, Lagha NB, Zeimoura L, et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 2000;436(4):351-6
45. Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004;93(3): 297-302
46. Rioux-Leclercq N, Fergelot P, Zerrouki S, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007;38(10): 1489-95
47. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26(22): 3743-8
48. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18
49. Escudier B, Ravaud A, Négrier S, et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety subgroups of patients and pharmacokinetic (PK) analysis. J Clin Oncol 2008;26(suppl 15):Abstract 5025
50. Pena C, Lathia C, Shan M, et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010; 16(19):4853-63
51. Garcia-Donas J, Leandro-Garcia LJ, Gonzalez Del Alba A, et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol 2013;24(9):2409-14
52. Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008; 123(2):395-400
53. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9(2): 802-11
54. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11(10): 3714-21
55. Choueiri TK, Regan MM, Rosenberg JE, et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010;106(6):772-8
56. Choueiri TK, Cheng S, Qu AQ, et al. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol 2012;31(8):1788-93
57. Schutz FA, Pomerantz MM, Gray KP, et al. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol 2013;14(1):81-7
58. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16(1): 68-73
59. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011; 12(12):1143-50
60. van der Veldt AA, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011;17(3): 620-9
61. Beuselinck B, Karadimou A, Lambrechts D, et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2013;108(4):887-900 . Genotyping of 16 key single nucleotide polymorphisms in 10 genes involved in sunitinib pharmacokinetics, pharmacodynamics and VEGFindependent angiogenesis in mRCC patients treated with first-line sunitinib. Single nucleotide polymorphism rs1128503 in ABCB1, rs4073054 in NR1/3 and rs307821 in VEGFR3 were significantly correlated with progressionfree survival and overall survival.
62. Beuselinck B, Karadimou A, Lambrechts D, et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib-a multicentric retrospective analysis. Acta Oncol 2013; 53(1):103-12
63. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32
64. Xu CF, Ball HA, Bing NX, et al. Association of genetic markers in angiogenesis-or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinoma. J Clin Oncol 2011;29(suppl 7): Abstract 303
65. Xu CF, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011;29(18):2557-64
66. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012; 72(13):3125-30
67. Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011;30(1):83-95
68. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56(11):1743-53
69. Li JF, Chu YW, Wang GM, et al. The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU Int 2009;103(3): 399-405
70. Polimeno M, Napolitano M, Costantini S, et al. Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int 2013;112(5): 686-96
71. Adotevi O, Pere H, Ravel P, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010;33(9): 991-8
72. Chung AS, Wu X, Zhuang G, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 2013; 19(9):1114-23
73. Shojaei F, Wu X, Qu X, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009;106(16):6742-7
74. Badoual C, Combe P, Gey A, et al. [PD-1 and PDL-1 expression in cancer: significance and prognostic value]. Med Sci (Paris) 2013;29(6-7):570-2
75. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66(7):3381-5
76. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007;13(6): 1757-61
77. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54 . Phases I-II study of antiprogrammed cell death-1 antibody in advanced melanoma, nonsmall-cell lung cancer, castrationresistant prostate cancer, renal cell or colorectal cancer. Objective responses were reported for mRCC, nonsmall-cell lung cancer and melanoma. Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response.
78. Fridman WH, Galon J, Pages F, et al. Prognostic and predictive impact of intraand peritumoral immune infiltrates. Cancer Res 2011;71(17):5601-5
79. Bromwich EJ, McArdle PA, Canna K, et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003;89(10): 1906-8
80. Hotta K, Sho M, Fujimoto K, et al. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer 2011;105(8):1191-6
81. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61(13):5132-6
82. Webster WS, Lohse CM, Thompson RH, et al. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer 2006; 107(1):46-53
83. Remark R, Alifano M, Cremer I, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013;19(15):4079-91 . Metastases from colorectal carcinoma and RCC have different immune infiltrates. The immune pattern (CD8+/DC-LAMP+ cell densities) has major prognostic value in these malignancies. It is reproducible from primary to metastatic tumors although with an opposite clinical impact. These observations highlight the role of the tumor cell in shaping its immune environment.
84. Kudoh S, Redovan C, Rayman P, et al. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J Immunother 1997;20(6):479-87
85. Tartour E, Latour S, Mathiot C, et al. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 1995;63(2):205-12
86. Gavalas NG, Tsiatas M, Tsitsilonis O, et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer 2012;107(11):1869-75
87. Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009; 27(2):235-41
88. Molina AM, Tickoo SK, Ishill N, et al. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol 2011;34(5):454-9
89. Rini BI, Jaeger E, Weinberg V, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006;98(4):756-62
90. Choueiri TK, Vaziri SA, Jaeger E, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180(3):860-5; discussion 865-866
91. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010;36(5):416-24
92. Boudou-Rouquette P, Ropert S, Mir O, et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist 2012;17(9):1204-12
93. Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66(2):357-71
94. Ravaud A, Schmidinger M. Clinical biomarkers of response in advanced renal cell carcinoma. Ann Oncol 2013;24(12): 2935-42
95. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90 . Updated results of the Phase III trial of first-line sunitinib versus interferon in mRCC patients showing significantly longer progression-free survival for sunitinib than for interferon.
96. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931-9
97. Qi WX, He AN, Shen Z, Yao Y. Incidence and Risk of hypertension with a novel multitargeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 2013; 76(3):348-57
98. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137-43 . Results of a Phase III trial of first-line bevacizumab plus IFN-a versus IFN-a alone in mRCC patients in which the combination arm showed better overall survival. However, the difference did not meet the predefined criteria for significance. Hypertension may be a clinical marker of outcome for treatment by bevacizumab plus IFN-a.
99. Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol 2012;30(14): 1678-85
100. Kappers MH, van Esch JH, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010;56(4):675-81
101. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24(9):1363-9
102. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008; 358(1):95-7
103. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103(9):763-73 . Sunitinib-associated hypertension (HTN) was associated with improved clinical outcomes without inducing any clinically significant increases in HTN-associated adverse events. This evidence supports the potential of HTN as a marker of efficacy.
104. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14(6):552-62
105. Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013;14(12):1233-42 . Phase II trial in which patients with mRCC treated with axitinib in first line who had no hypertension or Grades 3-4 adverse event, were randomized to axitinib dose-escalation (until 10 mg two-times a day) or axitinib standard dose (5 mg two-times a day). Results suggest that dose escalation was feasible for patients without hypertension which is suggested as a predicitve marker of axitinib exposure.
106. Poprach A, Pavlik T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol 2012;23(12):3137-43
107. Michaelson MD, Cohen DP, Li S, et al. Hand-foot syndrome as a potential biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Clin Oncol 2011;29(Suppl 7): Abstract 320
108. Davis MP, Figlin R, Hutson TE, et al. Asthenia and fatigue as potential biomarkers of sunitinib efficacy in metastatic renal cell carcinoma. Eur J Cancer 2011;47(Suppl 1): S135; Abstract 1139
109. Donskov F, Michaelson MD, Puzanov I, et al. Comparative assesment of sunitinibassociated adverse events as potential biomarkers of efficacy in metastatic renal cell carcinoma. Ann Oncol 2012; 23 (Suppl 9):Abstract 7850
110. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007; 17(4):351-5
111. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99(1):81-3
112. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinibinduced hypothyroidism: a prospective evaluation. Br J Cancer 2008;99(3):448-54
113. Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse Cancer 2011; 117(3):534-44
114. Sabatier R, Eymard JC, Walz J, et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma Ann Oncol 2012;23(3):714-21
115. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47
116. Aide N, Cappele O, Bottet P, et al. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003;30(9): 1236-45
117. Majhail NS, Urbain JL, Albani JM, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003;21(21):3995-4000
118. Ferda J, Ferdova E, Hora M, et al. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. Anticancer Res 2013;33(6):2665-72
119. Namura K, Minamimoto R, Yao M, et al. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18FFDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 2010;10:667
120. Revheim ME, Winge-Main AK, Hagen G, et al. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 2011;23(5):339-43
121. Ueno D, Yao M, Tateishi U, et al. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 2012;12(1): 162
122. Hugonnet F, Fournier L, Medioni J, et al. Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med 2011;52(7): 1048-55
123. Liu G, Jeraj R, Vanderhoek M, et al. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res 2011; 17(24):7634-44
124. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008;7(4):496-501
125. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008;26(28): 4572-8
126. Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006;42(15): 2472-9
127. Lassau N, Koscielny S, Albiges L, et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010; 16(4):1216-25
128. Lassau N, Vilgrain V, Taieb S, et al. Evaluation with DCE-US of antiangiogenic treatments in 539 patients allowing the selection of one surrogate marker correlated to overall survival. J Clin Oncol 2012; 30(Suppl):Abstract 4618
129. Lassau N, Chapotot L, Benatsou B, et al. Standardization of dynamic contrastenhanced ultrasound for the evaluation of antiangiogenic therapies: the French multicenter Support for Innovative and Expensive Techniques Study. Invest Radiol 2012;47(12):711-16
130. Fournier LS, Oudard S, Thiam R, et al. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2010; 256(2):511-8
131. Fournier L. Editorial comment: tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int 2012;110(11):1753-4
132. Iacovelli R, Lanoy E, Albiges L, Escudier B. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int 2012;110(11):1747-53
133. Ferte C, Koscielny S, Albiges L, et al. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: An integrated analysis of the TARGET and RECORD phase 3 trial data. Eur Urol 2013. [Epub ahead of print]
134. Oudard S, Thiam R, Fournier LS, et al. Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study. Eur J Cancer 2012; 48(10):1512-18
135. Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 2010;21(5):936-41 . Determination of a threshold for the CT evaluation of mRCC patients treated with sunitinib that best reflects patient outcomes. A-10% threshold for the sum of the longest diameters of target lesions was the most discriminating with regard to PFS and was confirmed by ROC analysis and by an external validation cohort.
136. Krajewski KM, Guo M, Van den, et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011;59(5):856-62
137. Abel EJ, Culp SH, Tannir NM, et al. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 2011;60(6):1273-9
138. Grunwald V, Lin X, Kalanovic D, et al. Tumor response is an independent prognostic factor in patients (pts) treated for metastatic renal cell carcinoma (mRCC). Eur J Cancer 2013;49(Suppl 2):Abstract 2702
139. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13):1753-9 . RECIST cannot be used to evaluate GISTs in patients treated with imatinib. However, CT findings correlated with tumor responses in these patients as evaluated by [18F]fluorodeoxyglucose PET.
140. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010;102(5):803-9
141. Schmidt N, Hess V, Zumbrunn T, et al. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol 2013;23(3):632-9
142. Nathan PD, Vinayan A, Stott D, et al. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010; 9(1):15-19
143. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 2010;194(1): 157-65
144. Smith AD, Shah SN, Rini BI, et al. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010;194(6):1470-8
145. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28(13):2144-50
146. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81 . Results of a Phase III trial of first-line temsirolimus, interferon alpha or both in the poor prognosis group of mRCC patients showing an advantage in overall survival for temsirolimus alone.
147. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6): 1287-96
148. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369(8):722-31 . Results of a noninferiority Phase III trial of first-line pazopanib versus sunitinib in mRCC patients showing equivalent progression-free survival but better tolerance for pazopanib.
149. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2): 125-34 . Results of the Phase III trial of sorafenib versus placebo in mRCC patients who had previously undergone immunotherapy showing significantly longer progression-free survival for sorafenib.
150. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116(18):4256-65